Core Viewpoint - Baili Tianheng successfully raised a total of 3.764 billion yuan through a private placement of A-shares, which will accelerate the development of its innovative drug pipeline and help the company enter the ranks of entry-level multinational corporations (MNCs) [1][4] Fundraising Details - The private placement attracted participation from 18 well-known domestic and international institutions, with a share price of 317 yuan, significantly above the base price of 266.02 yuan [1][2] - The issuance was highly anticipated in the market, with 30 investors submitting bids, and the final price set at 317 yuan per share, reflecting strong confidence in the company's R&D capabilities and growth prospects [1][4] Use of Proceeds - The raised funds will be fully allocated to innovative drug research and development projects, particularly focusing on the HIRE-ADC platform and GNC platform for innovative antibody drugs [2][3] - The ADC drug development platform will advance clinical trials for six ADC drugs, targeting over ten indications, including lung cancer and breast cancer [3] Clinical Development Plans - The company is conducting over 40 clinical trials for the BL-B01D1/iza-bren drug in China and the U.S., with several indications included in breakthrough therapy designations by the FDA and CDE [3] - The GNC platform will accelerate the clinical development of multi-specific antibodies, further enriching the company's innovative drug pipeline [3] Strategic Importance - This fundraising is a key initiative in the company's "Quality Improvement, Efficiency Enhancement, and Return to Action Plan" for 2025, with a significant increase in R&D investment [4] - The successful implementation of this private placement not only reflects market recognition of the value of innovative pharmaceutical companies but also marks the company's strategic commitment to becoming a global MNC under the guidance of the "Eight Policies" [4]

Fundraising Overview - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. has successfully raised a total of RMB 3,763,999,989.00 by issuing 11,873,817 shares at a price of RMB 317.00 per share, with a net amount of RMB 3,731,054,180.03 after deducting issuance costs [1][2] Fund Management and Regulatory Agreement - The company has established a special account for the management of the raised funds, ensuring that the funds are stored and used specifically for the innovation drug research and development projects [3][4] - A tripartite regulatory agreement has been signed among the company, China Construction Bank Chengdu Eighth Branch, and CITIC Securities, which outlines the management and usage of the raised funds [2][3] Key Provisions of the Agreement - The special account is exclusively for the storage and use of the raised funds, prohibiting any non-raising funds or alternative uses [3] - The company can invest temporarily idle funds in cash management products, provided it complies with relevant regulations and informs the sponsor [3][4] - The sponsor is responsible for ongoing supervision of the fund management and usage, with the authority to conduct investigations and request information from the bank [4][5] Reporting and Compliance - The bank is required to provide monthly account statements to the company and the sponsor, ensuring transparency in fund management [5][6] - Any withdrawals exceeding RMB 50 million or 20% of the net amount must be reported to the sponsor within five working days [5][6] - The agreement remains effective until all funds are fully utilized and the sponsor's supervision period concludes [6]

Core Viewpoint - Bailitianheng (688506) successfully completed its A-share private placement plan, raising a total of 3.764 billion yuan, aimed at accelerating the development of its innovative drug pipeline and enhancing its position among entry-level multinational corporations [1][2] Group 1: Fundraising Details - The private placement attracted participation from 18 well-known domestic and international institutions, with a subscription price set at 317 yuan per share [1] - The issuance price was determined to be 119.16% of the base price, which was set at 266.02 yuan per share [2] - The funds raised will be entirely allocated to innovative drug research and development projects, particularly focusing on the HIRE-ADC platform and GNC platform [2] Group 2: Clinical Trials and Product Pipeline - Bailitianheng is conducting 3 registration clinical trials in the U.S. for triple-negative breast cancer, EGFR-mutant non-small cell lung cancer, and urothelial carcinoma, with one indication included in the FDA's breakthrough therapy list [3] - In China, the company is running 11 Phase III clinical trials for various indications, with 5 indications recognized as breakthrough therapy by the CDE [3] - The company plans to commercialize its product iza-bren in China by 2026, with expectations for global market approval starting in 2029 [3] Group 3: Research and Development Investment - In the first half of 2025, Bailitianheng's R&D investment reached 1.039 billion yuan, a year-on-year increase of 90.74%, expanding its clinical pipeline to 15 drugs [3] - The private placement is a key initiative in the "Quality Improvement and Efficiency Recovery Action Plan" for 2025 [3]

四川百利天恒药业股份有限公司 北京市西城区金融大街7号北京英蓝国 际金融中心十八层1807-1819室 二〇二五年九月 2025年度向特定对象发行A股股票 发行情况报告书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 联席主承销商 深圳市前海深港合作区南山街道桂湾五 路128号前海深港基金小镇B7栋401 发行人全体董事、监事及高级管理人员声明 载、误导性陈述或重大遗漏，并对其真实性、准确性、完整性承担相应的法律责 任。 全体董事签名： 朱义 张苏娅 康健 卓识 朱海 DAVID GUOWEI WANG 李明远 俞雄 杨敏 3 四川百利天恒药业股份有限公司 年 月 日 2 本公司全体董事、监事及高级管理人员承诺本发行情况报告书不存在虚假记 肖耿 4 发行人全体董事、监事及高级管理人员声明 本公司全体董事、监事及高级管理人员承诺本发行情况报告书不存在虚假记 载、误导性陈述或重大遗漏，并对其真实性、准确性、完整性承担相应的法律责 任。 全体监事签名： 汪捷 刘亮 付婷 除董事以外的高级管理人员签名： 四川百利天恒药业股份有限公司 年 月 日 5 陈英格 | | | 发行人全体董事 ...

证明该审计报 告是否由具有执业许可的 您可使用手机"扫一扫"或进入"含 四川百利天恒药业股份有限公司 验资报告 截至 2025年9月15 日止 验资报告 第1页 立信会计师事务所(特殊普通合伙) O CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS 立信会计师事务所(特殊普通合伙) DO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP 验 资 报 告 信会师报字[2025]第ZA15003号 四川百利天恒药业股份有限公司全体股东: 我们接受委托,审验了四川百利天恒药业股份有限公司(以下简 称"贵公司")截至2025年9月15日止新增注册资本及股本情况。按 照国家相关法律法规以及协议、章程的要求出资,提供真实、合法、 完整的验资资料,保护资产的安全、完整是全体股东及贵公司的责任。 我们的责任是对贵公司新增注册资本的实收情况发表审验意见。我们 的审验是依据《中国注册会计师审计准则第1602 号-验资》进行的。 在审验过程中,我们结合贵公司的实际情况,实施了检查等必要的审 验程序。 贵公司原注册资本为人民币 401.0 ...

2025 年度向特定对象发行 A 股股票 发行过程及认购对象合规性之 法律意见书 北京市建国门北大街 8 号华润大厦 20 层 邮编：100005 电话：(86-10) 8519-1300 传真：(86-10) 8519-1350 junhebj@junhe.com 北京市君合律师事务所 关于四川百利天恒药业股份有限公司 北京市君合律师事务所 关于四川百利天恒药业股份有限公司 2025 年度向特定对象发行 A 股股票发行过程及认购对象合规性 之法律意见书 四川百利天恒药业股份有限公司： 北京市君合律师事务所（以下简称"本所"）接受四川百利天恒药业股份有 限公司（以下简称"发行人"或"公司"）的委托，指派律师以特聘法律顾问的 身份，就发行人 2025 年度向特定对象发行 A 股股票事宜（以下简称"本次发 行"），于 2025 年 4 月 15 日出具了《北京市君合律师事务所关于四川百利天恒 药业股份有限公司 2025 年度向特定对象发行 A 股股票之法律意见书》（以下简 称《原法律意见书》）和《北京市君合律师事务所关于四川百利天恒药业股份有 限公司 2025 年度向特定对象发行 A 股股票之律师工作报告》（以下 ...

证券代码：688506 证券简称：百利天恒 公告编号：2025-063 四川百利天恒药业股份有限公司 关于签署募集资金专户存储监管协议的公告 2、按照相关监管、自律规定履行内部程序并获得丙方同意后，甲方可在内 部决议授权范围内将专户内的暂时闲置的募集资金以符合《上海证券交易所科创 板上市公司自律监管指引第 1 号——规范运作》规定的现金管理产品形式存放， 现金管理应当通过专户或者公开披露的产品专用结算账户实施。甲方应将产品的 具体金额、存放方式、存放账户、存放期限等信息及时通知丙方。甲方承诺上述 产品提前支取、到期或进行转让后将资金及时转入本协议规定的募集资金专户进 行管理，并通知丙方。甲方实施现金管理不得影响募集资金投资计划的正常进行。 3、甲乙双方应当共同遵守《中华人民共和国票据法》、《支付结算办法》、《人 民币银行结算账户管理办法》等法律、行政法规、部门规章。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意四川百利天恒药业股份有限公司向特 定对象发行股票注册的 ...

四川百利天恒药业股份有限公司 关于向特定对象发行 A 股股票 发行情况报告书披露的提示性公告 证券代码：688506 证券简称：百利天恒 公告编号：2025-062 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川百利天恒药业股份有限公司（以下简称"公司"）本次向特定对象发行 A 股股票（以下简称"本次发行"）发行承销总结相关文件已经上海证券交易所 备案通过，公司将尽快办理本次发行新增股份的登记托管手续。 2025 年 9 月 19 日 特此公告。 四川百利天恒药业股份有限公司董事会 本次发行的具体情况详见公司同日在上海证券交易所（www.sse.com.cn）披 露的《四川百利天恒药业股份有限公司 2025 年度向特定对象发行 A 股股票发行 情况报告书》等相关文件。 ...

中信证券股份有限公司、 华泰联合证券有限责任公司、高盛（中国） 证券有限责任公司 关于 四川百利天恒药业股份有限公司 2025年度向特定对象发行A股股票 发行过程和认购对象合规性的报告 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 上海证券交易所： 四川百利天恒药业股份有限公司（以下简称"百利天恒""发行人"或"公 司"）向特定对象发行股票（以下简称"本次发行"）已获得中国证券监督管理委 员会（以下简称"中国证监会"）《关于同意四川百利天恒药业股份有限公司向特 定对象发行股票注册的批复》（证监许可〔2025〕1641 号）同意注册。 中信证券股份有限公司（以下简称"中信证券""保荐人（主承销商）"）作 为百利天恒本次发行的保荐人（主承销商），华泰联合证券有限责任公司、高盛 （中国）证券有限责任公司（以下简称"华泰联合""高盛中国"，中信证券、华 泰联合、高盛中国以下合称"联席主承销商"）作为本次发行的联席主承销商，根 据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》 （以下简称"《证券法》"）《证券发行与承销管理办法》（以下简称"《发行与承销 管理 ...

Core Insights - The Medical Health Index (980016) closed at 7114.13 points on September 17, with a slight increase of 0.22% and a trading volume of 34.146 billion yuan, indicating a turnover rate of 1.06% [1] Group 1: Index Performance - Among the constituent stocks of the Medical Health Index, 18 stocks rose while 30 stocks fell on the same day [1] - Bai Li Tian Heng led the gains with a rise of 4.08%, while Junshi Biosciences recorded the largest decline at 2.52% [1] Group 2: Top Constituents - The top ten constituents of the Medical Health Index are as follows: - WuXi AppTec (603259) with a weight of 13.58%, latest price at 109.29 yuan, and a market cap of 322.57 billion yuan, increased by 2.09% [1] - Hengrui Medicine (600276) with a weight of 10.87%, latest price at 70.13 yuan, and a market cap of 465.47 billion yuan, increased by 1.42% [1] - Mindray Medical (300760) with a weight of 8.17%, latest price at 66.66 yuan, and a market cap of 290.25 billion yuan, decreased by 0.09% [1] - United Imaging Healthcare (688271) with a weight of 4.14%, latest price at 151.60 yuan, and a market cap of 124.94 billion yuan, decreased by 0.90% [1] - Other notable constituents include Pianzai Shou (600436), Aier Eye Hospital (300015), and Fosun Pharma (600196) [1] Group 3: Capital Flow - The Medical Health Index constituents experienced a net outflow of 601 million yuan from major funds, while retail investors saw a net inflow of 615 million yuan [1] - Detailed capital flow for major stocks indicates that WuXi AppTec had a net inflow of 4.28 million yuan from major funds, while Hengrui Medicine saw a net outflow of 3.43 million yuan [2]